Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126410741 | 12641074 | 1 | I | 20160727 | 20160810 | 20160810 | EXP | IL-SIGMA-TAU US-2016STPI000595 | SIGMA TAU | FURLAN KC, KAKIZAKI P, VALENTE NYS, PIRES MC, CHARTUNI JCN. PRIMARY CUTANEOUS ASPERGILLOSIS AND IDIOPATHIC BONE MARROW APLASIA. ANAIS BRASILEIROS DE DERMATOLOGIA. 2016;91 (3):381 - 383 | 9.00 | YR | M | Y | 0.00000 | 20160810 | MD | IL | BR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126410741 | 12641074 | 1 | PS | ABELCET | AMPHOTERICIN BDIMYRISTOYLPHOSPHATIDYLCHOLINE, DL-DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL- | 1 | U | 50724 | INJECTION | ||||||||||
126410741 | 12641074 | 2 | SS | FLUCONAZOLE. | FLUCONAZOLE | 1 | U | 0 | |||||||||||
126410741 | 12641074 | 3 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126410741 | 12641074 | 1 | Aspergillus infection |
126410741 | 12641074 | 2 | Aspergillus infection |
126410741 | 12641074 | 3 | Aspergillus infection |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126410741 | 12641074 | OT |
126410741 | 12641074 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126410741 | 12641074 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |